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PCN72 ECONOMIC EVALUATION OF SUNITINIB VS. INTERFERON-A AND BEVACIZUMAB + INTERFERON-A IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (CCRM) -BRAZILIAN PRIVATE HEALTH SYSTEM PERSPECTIVE
Teich V 1 , Hashizume CM 2 , Marinho T 1 , Charbonneau C 3 , Naves A 2 1 Medinsight, Rio de Janeiro, RJ, Brazil, 2 Pfizer Brazil, Sao Paulo, SP, Brazil, 3 Pfizer, Inc., New York, NY, USA OBJECTIVES: Elaborate an economic evaluation based in a cost-effectiveness model to compare sunitinib versus interferon-α (IFNα) and bevacizumab + IFNα as first line therapy for metastatic renal clear cell carcinoma, in Brazilian Private Health System perspective. METHODS: A Markov model, with 6 weeks cycles and a 2-year time horizon was developed in Microsoft Excel to evaluate the cost-effectiveness of sunitinib vs. IFNα and bevacizumab + IFNα, considering resources from the Brazilian Private Health Care. The model considered that the patients received active treatment until drug fail. After progression confirmation, patients were treated with a second line of active treatment or best supportive care (progression monitoring and palliative treatment). Results were expressed as life-years (LY) gained, progression-free LY (PFLY) gained, treatment costs, and incremental cost-effectiveness ratios (ICER) RESULTS: In comparison with IFNα, sunitinib increases LY and PFLY by 0.08 and 0.33 years respectively, with ICER of R$324,172 (US$190,689 Purchasing Power Parity 2009, 1US$ = 1,7R$). In comparison with bevacizumab + IFNα, sunitinib was dominant as both more effective (with 0.04 LY and 0.09 PFLY gained) and less costly, with a negative ICER of R$ 2,169,212 (US$ 1,549,437) over 2 years, meaning a cost saving of R$ 2,169,212 over the combination therapy. CONCLUSIONS: This model suggests that when taking the perspective of the Brazilian Private Health Care System , sunitinib achieved overall cost saving with improved survival when compared with bevacizumab + IFNα in a 2 years time horizon. In comparison to IFNα, sunitinib promoted better results on efficacy parameters, with an incremental cost in the same time horizon.
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COST-EFFECTIVENESS ANALYSIS OF MULTIMODAL SCREENING FOR OVARIAN CANCER
Ding Y, Hay J University of Southern California, Los Angeles, CA, USA OBJECTIVES: The main objective was to assess cost-effectiveness of multimodal screening for ovarian cancer (Annual screening with CA125 marker, followed by transvaginal ultrasound for those at increased risk according to CA125 level) from the US societal perspective. The secondary objective was to facilitate an economic comparison between two different screening strategies (multimodal screening and ultrasound screening), which have been proven to be effective in improving early detection of ovarian cancer. METHODS: A lifetime incremental cost-effectiveness model was constructed to calculate the increase of costs, and QALYs gained by the multimodal screening. In this 'backward induction' model, the expected costs and outcomes for each 5-year time-interval are incorporated in subsequent 5-year time period calculations over the patient's entire lifetime. The sensitivity and specificity of screening, and the stage distribution of detected ovarian cancer by the screening were obtained from the NCT00058032 clinical trial. The model used a 3% discount rate and reported results in 2009 US dollars. RESULTS: Over a lifetime, multimodal screening was estimated to cost an additional $820 with an expected gain of 0.0037 quality adjusted life years (QALY) or an incremental cost-effectiveness ratio (ICER) of $221,622/ QALY compared to no screening for age 65-69 postmenopausal females. Compared with annual transvaginal ultrasound (TVU) screening, multimodal screening improves cost-effectiveness by avoiding unnecessary TVU and surgery, which are risky to the patient and costly to the health care system. Cancer incidence rates and time required for screening exhibited substantial impact on the model from sensitivity analyses. CONCLUSIONS: Multimodal screening is not clearly cost-effective, compared to commonly accepted willingness-to-pay thresholds in oncology ($120,000-$150,000/QALY). If high risk women were selected for multimodal screening or if the screening was administered as part of another medical office visit in order to decrease the time required for screening test, the ICER could be lower than $120,000/QALY. We conducted an economic evaluation with cost and outcome data from a randomized controlled trial of promotora led interventions to increase cervical cancer screening among three populations of low income Hispanic women. METHODS: Hispanic women of Mexican origin, age 21 to 65, with no previous cervical cancer, no hysterectomy, and no Pap test within the last 3 years from El Paso, Houston, TX and Yakima Valley, WA were randomly assigned to four intervention arms, control, video, flip chart, and full (combination of video and flip chart) intervention. Micro costing, including recruitment cost, from both payer and client perspectives were used to estimate intervention costs. Effectiveness measures were the prevalence of a self-reported pap test within 6 months after the intervention, analyzed under the condition of intention-to-treat. Incremental cost effectiveness ratios (ICERs) were the incremental cost per additional women screened. Uncertainty was examined with sensitivity analyses. RESULTS: The total cost per participant, was $216 for video, $219 for flip chart, and $223 in the full intervention. The proportion of women reporting a Pap test was 0.261 in the control arm, 0.484 in the video arm, 0.515 in the flipchart arm and 0.568 in the full intervention arm. The ICERs were $968 comparing the control arm to the movie, $94 comparing the movie to flip chart arm and $72 comparing flip chart to the full intervention arm. CONCLUSIONS: The promotora led full interventions had important and statistically significant effects on screening behavior and compare favorably with the other two strategies designed to promote cervical cancer screening in the study. The study provides economic information for health educators in designing and budgeting promotora based cancer screening promotion programs for low income Hispanic women.
PCN74 COST-EFFECTIVENESS OF PROMOTORA LED HEALTH EDUCATION INTERVENTIONS TO INCREASE CERVICAL CANCER SCREENING AMONG LOW INCOME HISPANIC WOMEN
PCN75 COST-EFFECTIVENESS ANALYSIS OF EGFR MUTATION TESTING IN PATIENTS WITH ADVANCED NON SMALL-CELL LUNG CANCER (ANSCLC) TREATED WITH GEFITINIB OR CARBOPLATIN-PACLITAXEL
Arrieta O 1 , Anaya P 2 , López RJ 2 , Polanco AC 2 1 National Cancer Institute of Mexico, D.F., Mexico, 2 AstraZeneca, Naucalpan, Mexico OBJECTIVES: To assess the cost-effectiveness of an EGFR mutation testing strategy when considering 1 st -line therapy of aNSCLC with gefitinib for mutation positive and carboplatin-paclitaxel (CP) for mutation negative disease. METHODS: A Discrete Event Simulation (DES) was designed to emulate two strategies for treating patients with aNSCLC. In the first strategy, patients were tested for EGFR genetic mutation and given gefitinib if positive and CP if negative. In the second strategy patients were not tested for genetic mutation and all of them received CP treatment. Probabilities for adverse events and progression-free survival (PFS) were obtained from the IPASS clinical study (Mok et al 2009) . The mutation rate used was 13% and a sensitivity analysis was run over this variable. A Markov model using micro simulation was also built to compare results of the DES model and assure internal validity. Both models were run 10 times with 1000 patients for each strategy. Cost-effectiveness ratios were obtained for the testing and not-testing strategies and particularly for positive tested patients treated with gefitinib. RESULTS: Mean PFS (generated by DES) of tested patients with mutation positive disease treated with gefitinib was 11.51 (95% CI, 11.10-11.92) months. PFS of patients who where tested for EGFR mutation (positive and negative) was 7.57 (95% CI, 7.50-7.64) months. Patients in the second strategy (without testing) yielded 7.11(95% CI, 7.05-7.17) progression-free months. Incremental cost-effectiveness ratio (ICER) of the testing strategy (including test cost) over the not-testing strategy was $1379.49 (95% IC, $1102.10-$1656.88) per progression-free month. CONCLUSIONS: According to this analysis, testing aNSCLC patients for
